Literature DB >> 17407168

The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent?

E J M Bierman1, H C Comijs, C M Gundy, C Sonnenberg, C Jonker, A T F Beekman.   

Abstract

OBJECTIVE: This study investigates the effects of benzodiazepine (BZ) use on cognitive performance in elderly persons in a longitudinal design. STUDY DESIGN AND
SETTING: Data were obtained from the Longitudinal Aging Study Amsterdam (LASA), in the Netherlands. 2,105 respondents (>/=62 years of age) were included and had repeated measurements over a period of 9 years. For all BZs the type, dosage, frequency and duration of use was measured. The equivalent of a dose of diazepam was determined with regard to type and dosage and a cumulative dosage was calculated. General cognitive functioning was measured with the Mini-Mental State Examination, information processing speed was measured with the coding task, fluid intelligence with Raven's Coloured Progressive Matrices and episodic memory with the Auditory Verbal Learning Test. Multilevel analyses were used to investigate the relationship between BZ use and cognitive decline.
RESULTS: A negative effect of BZ use on cognitive performance was found. However, the effect sizes were very small.
CONCLUSION: This study suggests that both duration and cumulative exposure to BZ has a small negative effect on the long-term cognitive functioning of elderly people in the community.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407168     DOI: 10.1002/gps.1811

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  23 in total

1.  Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort.

Authors:  Olivia Boeuf-Cazou; Bienvenu Bongue; David Ansiau; Jean-Claude Marquié; Maryse Lapeyre-Mestre
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

Review 2. 

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

Review 3.  Optimizing medications in older adults with cognitive impairment: Considerations for primary care clinicians.

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

Review 4.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 5.  The efficacy and safety of newer anticonvulsants in patients with dementia.

Authors:  Christian R Dolder; Kimberly L Nealy
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

6.  Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.

Authors:  Juha Puustinen; Ritva Lähteenmäki; Päivi Polo-Kantola; Paula Salo; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Eur J Clin Pharmacol       Date:  2013-12-12       Impact factor: 2.953

Review 7.  The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge.

Authors:  Antoine Pariente; Sophie Billioti de Gage; Nicholas Moore; Bernard Bégaud
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

8.  Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation.

Authors:  Philipe de Souto Barreto; Maryse Lapeyre-Mestre; Philippe Cestac; Bruno Vellas; Yves Rolland
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

Review 9.  Benzodiazepine harm: how can it be reduced?

Authors:  Malcolm Lader
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

10.  Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study.

Authors:  Hélène Amieva; Céline Meillon; Catherine Helmer; Pascale Barberger-Gateau; Jean François Dartigues
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.